Kamada Ltd.
A biopharmaceutical company specializing in plasma-derived protein therapeutics.
KMDA | TA
Overview
Corporate Details
- ISIN(s):
- IL0010941198
- LEI:
- Country:
- Israel
- Address:
- 2 Holzman St, Science Park, 7670402 Rehovot
- Website:
- https://www.kamada.com
- Sector:
- Manufacturing
Description
Kamada Ltd. is a vertically integrated global biopharmaceutical company specializing in plasma-derived protein therapeutics. The company develops, manufactures, and commercializes a portfolio of products for rare and serious conditions, with a focus on therapeutic areas such as Alpha-1 Antitrypsin Deficiency (AATD) and Cytomegalovirus (CMV) prevention in transplant patients. Kamada utilizes a proprietary platform technology for advanced protein extraction and purification from human plasma. In addition to its marketed products, the company maintains a development pipeline of new therapies, including an inhaled treatment for AATD.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2023-05-24 16:08 |
Kamada Announces Chief Financial Officer Chaime Orlev to Remain in Role and App…
|
English | 208.3 KB | ||
| 2023-05-24 16:08 |
Kamada Announces Chief Financial Officer Chaime Orlev to Remain in Role and App…
|
English | 36.2 KB | ||
| 2023-05-24 16:01 |
Kamada Announces $60 Million Private Placement with FIMI Opportunity Funds
|
English | 278.8 KB | ||
| 2023-05-24 16:01 |
Kamada Announces $60 Million Private Placement with FIMI Opportunity Funds
|
English | 36.1 KB | ||
| 2023-05-17 16:02 |
First Quarter 2023 Financial Results and Host Conference Call on May 24, 2023
|
English | 120.1 KB | ||
| 2023-05-17 16:02 |
First Quarter 2023 Financial Results and Host Conference Call on May 24, 2023
|
English | 36.1 KB | ||
| 2023-05-16 16:01 |
amada Announces Receipt of Marketing Authorization for Glassia® for Treatment o…
|
English | 148.0 KB | ||
| 2023-05-16 16:01 |
amada Announces Receipt of Marketing Authorization for Glassia® for Treatment o…
|
English | 36.2 KB | ||
| 2023-05-03 16:02 |
U.S. FDA Approval of its Application to Manufacture CYTOGAM® at the Company’s
…
|
English | 292.1 KB | ||
| 2023-05-03 16:02 |
U.S. FDA Approval of its Application to Manufacture CYTOGAM® at the Company’s
…
|
English | 36.1 KB | ||
| 2023-03-15 14:34 |
Kamada Issues 2023 CEO Letter to Shareholders; Financial Results presentation
|
English | 3.8 MB | ||
| 2023-03-15 14:34 |
Kamada Issues 2023 CEO Letter to Shareholders; Financial Results presentation
|
English | 36.0 KB | ||
| 2023-03-15 14:30 |
Kamada Files Annual Report for the Year Ended December 31, 2022
|
English | 118.9 KB | ||
| 2023-03-15 14:30 |
Kamada Files Annual Report for the Year Ended December 31, 2022
|
English | 36.0 KB | ||
| 2023-03-15 14:27 |
FORM 20-F For the fiscal year ended December 31, 2022
|
Hebrew (modern) | 7.6 MB |
Automate Your Workflow. Get a real-time feed of all Kamada Ltd. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Kamada Ltd.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Kamada Ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
